Q32 Bio Inc. QTTB
8.76 USD +0.05 (+0.57%)
At closeNov 3, 2026, 4:00 PM EST
8.76 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
8.68 Day range 9.04
1.91 52-week range 23.57
- YTD
- +163.86%
- 1 year
- +240.86%
News
defenseworld.net Head to Head Contrast: Q32 Bio (NASDAQ:QTTB) & Applied Therapeutics (NASDAQ:APLT) Q32 Bio (NASDAQ: QTTB - Get Free Report) and Applied Therapeutics (NASDAQ: APLT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two…
benzinga.com Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $40 Leerink Partners analyst Will Soghikian initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Outperform rating and announces Price Target of $40.
benzinga.com Q32 Bio Announces Additional 36-Week Results And Initial Findings From The 16-Week Off-Drug Period From Part B Of The SIGNAL-AA Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA; Clinically Meaningful Efficacy Data Observed On Primary And Key Secondary Endpoints At Week 36; Robust Durability, Including Maintenance And Deepening Of Response These results were presented across a late-breaking oral and poster presentation at the European Academy of Dermatology and Venereology ("EADV") Congress 2026. Q32 Bio previously announced topline…
prnewswire.com Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 -- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 -- -- Robust durability, including maintenance and deepening of response, observed following the…- benzinga.com Jefferies Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $29 Jefferies analyst Maury Raycroft initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Buy rating and announces Price Target of $29.
seekingalpha.com Q32 Bio: Durable Hair Regrowth Remains The Goal Q32 Bio'S bempikibart could offer lasting hair regrowth in alopecia areata, but its potential advantage still depends on broader clinical validation. For now, QTTB's improved financing gives them…- benzinga.com Q32 Bio Presents Additional 36-Week Data From Its Part B Of SIGNAL-AA Phase 2a Clinical Study Of Bempikibart At European Academy Of Dermatology And Venereology Congress Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases,…
prnewswire.com Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 -- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart…
seekingalpha.com Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
prnewswire.com Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D. -- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development -- -- Dr. Hershberger is a drug…
zacks.com Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts…
defenseworld.net Q32 Bio Inc. $QTTB Stock Position Increased by Atlas Venture Life Science Advisors LLC Atlas Venture Life Science Advisors LLC grew its position in Q32 Bio Inc. (NASDAQ: QTTB) by 29.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned…
prnewswire.com Q32 Bio to Participate in Upcoming September Investor Conferences WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and…
benzinga.com Morgan Stanley Initiates Coverage On Q32 Bio with Overweight Rating, Announces Price Target of $34 Morgan Stanley analyst Judah Frommer initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Overweight rating and announces Price Target of $34.
zacks.com Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the…
benzinga.com Q32 Bio Q2 EPS $(0.44) Beats $(0.54) Estimate Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.54) by 18.52 percent. This is a 43.59 percent increase over losses of $(0.78) per…
prnewswire.com Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at…
zacks.com Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
benzinga.com Twilio To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on top names. For a complete view, see analyst ratings page. See how others view these stocks.- benzinga.com HC Wainwright & Co. Maintains Buy on Q32 Bio, Raises Price Target to $36 HC Wainwright & Co. analyst Joseph Pantginis maintains Q32 Bio (NASDAQ:QTTB) with a Buy and raises the price target from $13 to $36.
seekingalpha.com Playing The Biotech Breakout With Insiders Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking…
zacks.com Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out.
seekingalpha.com Q32 Bio: Bempikibart's Progress Keeps Me Bullish Q32 Bio's Part B data showed meaningful hair regrowth in severe alopecia areata, including for JAK-experienced patients. Bempikibart also seems to be relatively safe, and its treatment benefits…
benzinga.com Why Is Q32 Bio Stock Falling Wednesday? Q32 Bio (QTTB) stock slips after pricing a $200M public offering at $18.25. Get the details on the deal and share reaction.
zacks.com Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
prnewswire.com Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other…
benzinga.com $100 Invested In Q32 Bio 5 Years Ago Would Be Worth This Much Today Q32 Bio (NASDAQ:QTTB) has outperformed the market over the past 5 years by 11.82% on an annualized basis producing an average annual return of 23.91%. Currently, Q32 Bio has a market capitalization…
benzinga.com Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-market. Other stocks moving lower in pre-market.
fool.com Why Q32 Bio Stock Skyrocketed Today The biotech is advancing a potential treatment for a common autoimmune disease.
benzinga.com Q32 Bio Launches $200M Public Offering Of Its Common Stock Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases,…
seekingalpha.com Q32 Bio: 'Strong Buy' On Solid Bempikibart SIGNAL-AA Study Data And Catalysts Q32 Bio upgraded to "Strong Buy" after positive phase 2a SIGNAL-AA results for bempikibart in severe alopecia areata. QTTB achieved its primary efficacy endpoint, with 35.3% mean SALT score reduction…
prnewswire.com Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and…- benzinga.com Wells Fargo Upgrades Q32 Bio to Overweight, Announces $66 Price Target Wells Fargo analyst Derek Archila upgrades Q32 Bio (NASDAQ:QTTB) from Equal-Weight to Overweight and announces $66 price target.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose…
benzinga.com Crude Oil Surges Over 5%; Twin Vee Powercats Shares Jump US stocks dip, Nasdaq falls 1%. Dow down 0.34%. Energy shares up 2.1%, tech down 1.2%. Micron Tech drops 5%. Commodities mixed. European and Asian markets close mixed.- benzinga.com Oppenheimer Maintains Outperform on Q32 Bio, Raises Price Target to $40 Oppenheimer analyst Jay Olson maintains Q32 Bio (NASDAQ:QTTB) with a Outperform and raises the price target from $20 to $40.
benzinga.com US Stocks Mixed; Dow Gains Over 100 Points US stocks mixed, Dow up 100 points. Energy up 2.1%, tech down 1.1%. LogProstyle Inc shares rise on earnings. Oil up 3.9%, gold down 1%.
benzinga.com Q32 Bio Stock Soars After Patchy Hair Loss Study - Here's Why Q32 Bio reported positive Phase 2a data for bempikibart in severe alopecia areata, showing hair regrowth and favorable safety.
benzinga.com Stock Market Today: Dow Jones, Nasdaq 100, S&P 500 Futures Slips as US and Iran Exchange Strikes— Saratoga, Exxon Mobil, Levi's Strauss In Focus (UPDATED) U.S. stock futures were mixed on Monday, as the Dow Jones index advanced, while the Nasdaq 100 and S&P 500 indices fell.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million. Q32 Bio (NASDAQ:QTTB) stock rose 65.92% to…
benzinga.com Market-Moving News for July 13th QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial on Monday, July 13, 2026. AGEN: 36% |…- benzinga.com Q32 Bio Announces 36-Week Topline Results From Part B Of SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA -- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis ---- 40.0% of patients…
benzinga.com Why Q32 Bio Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket Gainers: Q32 Bio up 29.6%, Mint up 75.8%, Fast Track up 58.2%, eLong up 33.4%, Sobr Safe up 29.2%, Eshallgo up 20.3%, Curis up 10.9%, Sky Quarry up 10.6%, Accuray up 9.5%, Bitzero up 5.5%. Losers:…
benzinga.com FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday U.S. stock futures down today, FB Financial, Smith Micro Software, LogProstyle, Veraxa Biotech, and Q32 Bio among stocks to watch. More premarket coverage at Benzinga.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares…
benzinga.com Q32 Bio To Reveal 36-Week Topline Results From Part B Of The SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe Aa On July 13, 2026 Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases,…
benzinga.com Why Is Q32 Bio Stock Gaining Friday? Q32 Bio ($QTTB) jumps in premarket trading after securing a $55M private placement to fund its autoimmune pipeline. Read more.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session